Skip to search boxSkip to navigationSkip to main content

Stimuli-responsive theranostic system: A promising approach for augmented multimodal imaging and efficient drug release

  • Ayşegül Demiral
    ,
  • S. İrem Goralı
    ,
  • Hülya Yılmaz
    ,
  • Nihan Verimli
    ,
  • ,
  • S. Sibel Erdem(corresponding author)
*Corresponding author for this work
  • Istanbul Medipol University
    ,
  • Research Institute for Health Science and Technologies (SABITA)
    ,
  • Sabanci University
    ,
  • University of South Florida
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Destruction of drug resistant and invisible micro-tumors requires innovative screening and treatment modalities. Theranostic nanosystems offering multimodal imaging and therapy are attractive platforms with potential to make micro-tumors visible to clinicians. Gold nanoparticles (AuNPs) are intrinsic theranostic agents and act as fluorescence quenchers. They can be easily transformed to multimodal imaging and combination therapy agents by combining them with various adjuvant therapies such as photodynamic therapy. In this study, we developed a highly specific, hybrid theranostic agent that is only activated when it meets with its stimuli at the site of interest. Surface-coated AuNPs were modified with Cathepsin B cleavable peptide (stimuli responsive linker) and Verteporfin (photosensitizer and fluorescence imaging agent). Unless the theranostic system meets with the internal stimuli in tumor cells, fluorescence is quenched due to AuNP-Verteporfin and Verteporfin-Verteporfin interactions. Following cellular internalization of the theranostic agent, fluorescence is gained by Cathepsin B cleavage and phototoxicity is initiated by light. The system was efficiently internalized by SKOV-3 cells and demonstrated high specificity towards its stimuli. In comparison to Verteporfin, ∼14-fold fluorescence increase, 81% fluorescence recovery and comparable toxicity were achieved. The system is a promising candidate for multimodal imaging and dual treatment to destroy the micro-tumors.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 9-23 (15 pages)

Journal (Volume, Issue Number)

European Journal of Pharmaceutics and Biopharmaceutics (Volume 177)

Publication milestones

  • Published - 08/2022

Publication status

Published - 08/2022

ISSN

0939-6411

Publication IDs

  • Scopus: 85131749341
  • PubMed: 35671914

Publication metrics

Metrics

Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
8
Citation count
5

Funding Details

The study described in this paper was supported by a grant from the Scientific and Technological Research Council of Turkey, TÜBİTAK with grant number 119S219. We would like to thank the SABITA administration for its support. We also thank Assist. Prof. Bilgesu Onur Sucu for her assistance in acquiring LC-MS data. The study described in this paper was supported by a grant from the Scientific and Technological Research Council of Turkey, TÜBİTAK with grant number 119S219.
FunderFunding number
TÜBITAK
119S219